Log in

NASDAQ:ALEC - Alector Stock Price, Forecast & News

$21.87
-2.26 (-9.37 %)
(As of 04/2/2020 01:16 AM ET)
Today's Range
$21.51
Now: $21.87
$23.50
50-Day Range
$21.09
MA: $27.41
$31.34
52-Week Range
$13.64
Now: $21.87
$35.93
Volume459,683 shs
Average Volume667,258 shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALEC
CUSIPN/A
CIKN/A
Phone415-231-5660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.22 million
Book Value$2.83 per share

Profitability

Net Income$-105,390,000.00
Net Margins-496.65%

Miscellaneous

Employees91
Market Cap$1.72 billion
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.


Alector (NASDAQ:ALEC) Frequently Asked Questions

How has Alector's stock been impacted by COVID-19 (Coronavirus)?

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC stock has decreased by 12.2% and is now trading at $21.87. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alector?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alector.

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Alector.

How were Alector's earnings last quarter?

Alector Inc (NASDAQ:ALEC) issued its quarterly earnings data on Tuesday, March, 24th. The company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.03. The firm had revenue of $6 million for the quarter, compared to the consensus estimate of $9.60 million. Alector had a negative net margin of 496.65% and a negative return on equity of 45.56%. View Alector's earnings history.

What price target have analysts set for ALEC?

5 analysts have issued 1 year price targets for Alector's shares. Their forecasts range from $28.00 to $28.00. On average, they expect Alector's share price to reach $28.00 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View analysts' price targets for Alector.

Has Alector been receiving favorable news coverage?

Media stories about ALEC stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alector earned a news impact score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAlector.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Cisco Systems (CSCO), Alibaba Group (BABA), Advanced Micro Devices (AMD), AT&T (T), Verizon Communications (VZ), Johnson & Johnson (JNJ), Gossamer Bio (GOSS) and Kaleido Biosciences (KLDO).

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
  • Dr. Robert S. King, Chief Devel. Officer (Age 56)
  • Dr. Asa Abeliovich M.D., Ph.D., Co-Founder

When did Alector IPO?

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $21.87.

How big of a company is Alector?

Alector has a market capitalization of $1.72 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe. View additional information about Alector.

What is Alector's official website?

The official website for Alector is http://www.alector.com/.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]


MarketBeat Community Rating for Alector (NASDAQ ALEC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Featured Article: What is a Derivative?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel